TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02652260
Drug: Placebo to Doravirine, Tenofovir, Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
Study: NCT03272802
Drug: Edaravone
Normalized name: Edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
Study: NCT03272802
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
Study: NCT01497041
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
Study: NCT01497041
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
Study: NCT00716066
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00716066
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00716066
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00716066
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00716066
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04306471
Drug: Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
Study: NCT00114400
Drug: vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00114400
Drug: vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00068068
Drug: Talaporfin sodium (LS11)
Normalized name: Talaporfin
DrugBank: Talaporfin (DB11812)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00694850
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
Study: NCT01537666
Drug: IV vancomycin hydrochloride
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin hydrochloride solution for intravenous administration
Study: NCT02247726
Drug: RSV F vaccine (0.5mL injection)
Normalized name: RECOMBINANT STABILIZED RSV A PREFUSION F ANTIGEN
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02352025
Drug: S-equol
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
Study: NCT01527149
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01527149
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT01527149
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01986049
Drug: Bupivicaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03235245
Drug: Nivolumab + Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
Study: NCT03235245
Drug: Encorafenib + Binimetinib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
Study: NCT03036891
Drug: Naloxegol 25 MG Oral Tablet [Movantik]
Normalized name: naloxegol 25 MG Oral Tablet [Movantik]
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
Study: NCT02723955
Drug: feladilimab (GSK3359609)
Normalized name: Feladilimab
DrugBank: Feladilimab (DB16415)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02723955
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03145857
Drug: [68]Ga-HA-DOTATATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
Study: NCT02723955
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02723955
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02723955
Drug: Paclitaxel plus Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02723955
Drug: Gemcitabine plus Carboplatin
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02723955
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02723955
Drug: Cobolimab
Normalized name: Cobolimab
DrugBank: Cobolimab (DB16372)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02723955
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04300647
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Study: NCT04300647
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT04454281
Drug: Naloxone Hydrochloride 0.4 MG/ML
Normalized name: naloxone hydrochloride 0.4 MG/ML
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug will be topically applied to the corneal surface then study evaluations will ensue.
Study: NCT01434017
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
Study: NCT01434017
Drug: Dexamethasone and droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
Study: NCT01434017
Drug: Dexamethasone and Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
Study: NCT00242814
Drug: Micardis
Normalized name: Micardis
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00242814
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410761
Drug: ZD6474 (Vandetanib)
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily oral tablet
Study: NCT03657212
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
Study: NCT02006472
Drug: Pridopidine
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg and 45 mg capsules
Study: NCT00497744
Drug: Intraperitoneal Cefepime
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01273506
Drug: tapentadol (CG5503) ER 25-mg TRF
Normalized name: Tapentadol Extended-Release Tablets
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg TRF single oral dose
Study: NCT01273506
Drug: tapentadol (CG5503) ER 50-mg TRF
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg TRF single oral dose
Study: NCT02500706
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
Study: NCT02500706
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
Study: NCT02500706
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
Study: NCT01053806
Drug: 5-Azacytidine and Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
Study: NCT00001343
Drug: Humatrope
Normalized name: Humatrope
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001343
Drug: Oxandrolone
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04293081
Drug: Preemptive chlorepheniramine maleate intravenous injection
Normalized name: Chlorpheniramine Maleate
DrugBank: Pheniramine (DB01620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
Study: NCT01326481
Drug: TRC105
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
DrugBank: Carotuximab (DB06322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00842504
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mg/kg IV once over 1 hour
Study: NCT00307736
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
Study: NCT00307736
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
Study: NCT00307736
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
Study: NCT01005875
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexavar in bottles of 120 tables
Study: NCT02736149
Drug: ubenimex
Normalized name: Ubenimex
DrugBank: Ubenimex (DB03424)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00441909
Drug: UC-781
Normalized name: UC-781
DrugBank: UC-781 (DB05871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% UC-781 Vaginal Gel
Study: NCT00441909
Drug: UC-781 placebo
Normalized name: Astri-UC
DrugBank: UC-781 (DB05871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Gel Placebo
Study: NCT00603317
Drug: Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
Study: NCT00603317
Drug: Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
Study: NCT03686488
Drug: TAS 102
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS 102 35 mg will be administered orally twice daily every 2 weeks.
Study: NCT03686488
Drug: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
Study: NCT01156246
Drug: Dapagliflozin/Metformin
Normalized name: DAPAGLIFLOZIN/METFORMIN
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
Study: NCT00203294
Drug: lidocaine, bupivicaine and saline
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
Study: NCT00203294
Drug: lidocaine plus bupivicaine plus triamcinolone (steroid)
Normalized name: benzalkonium / lidocaine Topical Ointment [Alocane Plus]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
Study: NCT03768063
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
Study: NCT03768063
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered as directed per the parent study.
Study: NCT03768063
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib will be administered as directed per the parent study.
Study: NCT03768063
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib will be administered as directed per the parent study.
Study: NCT03768063
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib will be administered as directed per the parent study.
Study: NCT03768063
Drug: FAP IL2V
Normalized name: AVA-6000 (FAP-activated doxorubicin prodrug)
DrugBank: AVA-6000 (DB17398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAP IL2V will be administered as directed per the parent study.
Study: NCT03768063
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax will be administered as directed per the parent study.
Study: NCT03768063
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide will be administered as directed per the parent study.
Study: NCT03768063
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered as directed per the parent study.
Study: NCT03768063
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be administered as directed per the parent study.
Study: NCT03768063
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib will be administered as directed per the parent study.
Study: NCT03768063
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib will be administered as directed per the parent study.
Study: NCT03768063
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered as directed per the parent study.
Study: NCT03768063
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered as directed per the parent study.
Study: NCT03768063
Drug: Emactuzumab
Normalized name: Emactuzumab
DrugBank: Emactuzumab (DB14905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab will be administered as directed per the parent study.
Study: NCT03768063
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib will be administered as directed per the parent study.
Study: NCT00515866
Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00515866
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous injection
Study: NCT02935010
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: proton pump inhibitor
Study: NCT02935010
Drug: Bismuth Potassium Citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT02935010
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic for H. pylori eradication
Study: NCT02935010
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic for H. pylori eradication
Study: NCT02935010
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic for H. pylori eradication
Study: NCT00483600
Drug: fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injections of 2.5mg every other day for 4 weeks
Study: NCT01684085
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam 1 mg
Study: NCT00208572
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00250094
Drug: Topotecan and VP16
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days.
Study: NCT02256150
Drug: Mizoribine (MZR)
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01397097
Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon)
Normalized name: etonogestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
Study: NCT02950051
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
Study: NCT00385190
Drug: HCV-796
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02950051
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
Study: NCT02950051
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d
Study: NCT02950051
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d